Xiangkun Wu

Xiangkun Wu

Auto-generated profile, based on publicly available information

Xiangkun Wu

Department of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
LYLihua Yan
Lihua Yan
XWXiangkun Wu
Xiangkun Wu
XYXianzhe Yin
Xianzhe Yin
FDFeng Du
Feng Du
YLYongxi Liu
Yongxi Liu
XDXunmeng Ding
Xunmeng Ding
Long non‐coding RNA (lncRNA) plays important roles in tumour progression. Accumulating studies demonstrated that lncRNA colon cancer‐associated transcript 2 (CCAT2) acted as an oncogene in many tumours. However, the role of CCAT2 in the development of osteosarcoma has not been elucidated. In our study, we indicated that CCAT2 expression was up‐regulated in osteosarcoma tissues and cell lines (SOSP‐9607, MG‐63, U2OS and SAOS‐2). In addition, osteosarcoma cases with higher CCAT2 expression had a poorer disease‐free survival and shorter the overall survival time compared to those with lower expression. Overexpression of CCAT2 promoted osteosarcoma cell proliferation, invasion and cell cycle. Furthermore, ectopic expression of CCAT2 increased the expression of mesenchymal markers N‐cadherin, vimentin and snail and reduced the expression of N‐cadherin marker E‐cadherin. CCAT2 overexpression promoted the LATS2 and c‐Myc expression in osteosarcoma cell. These data indicated that CCAT2 served as an oncogene in osteosarcoma and promoted osteosarcoma cell proliferation, cell cycle and invasion.

14 September 2019 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
XWXiangkun Wu
Xiangkun Wu
ZZZhijian Zhao
Zhijian Zhao
HSHongling Sun
Hongling Sun
CCChao Cai
Chao Cai
ZLZhilin Li
Zhilin Li
YLYongda Liu
Yongda Liu

8 July 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
XWXiangkun Wu
Xiangkun Wu
DLDaojun Lv
Daojun Lv
Ming LeiMing Lei
Ming Lei
CCChao Cai
Chao Cai
ZZZhijian Zhao
Zhijian Zhao
YLYongda Liu
Yongda Liu
The time and speed of biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy (RP) is highly variable. Stratification methods based on TNM staging and Gleason score (GS) do not allow the identification of patients at risk of BCR following RP. Therefore, the aim of the present study was to identify molecular signatures that can predict BCR risk effectively and facilitate treatment‑related decisions for patients with PCa. RNA sequencing data and corresponding clinical data were downloaded from The Cancer Genome Atlas (TCGA) and Oncomine databases. Bioinformatics analysis was performed to identify differentially expressed genes in patients with GS=6 and GS ≥7. Cox regression models were used to determine the PCa signature (PCasig) and a clinical nomogram for the prediction of BCR. The performance of nomograms was assessed using time‑dependent receiver operating characteristic curves and the concordance index (C‑index). A PCasig comprising 10 genes, including SEMG2, KCNJ16, TFAP2B, SYCE1, KCNU1, AFP, GUCY1B2, GRIA4, NXPH1 and SOX11, was significantly associated with BCR, which was identified in TCGA cohort [hazard ratio (HR), 5.18; 95% CI, 3.241‑8.272; C‑index, 0.777] and validated in the Oncomine cohort (HR, 2.78; 95% CI, 1.39‑5.54; C‑index, 0.66). The expression levels of SEMG2, KCNJ16 and TFAP2B were downregulated in patients with GS ≥7. The expression levels of SYCE1, KCNU1, AFP, GUCY1B2, GRIA4, NXPH1 and SOX11 were upregulated in patients with GS ≥7. The clinical nomogram was constructed based on the GS and pathologic T stage (HR, 4.15; 95% CI, 1.39‑5.54; C‑index, 0.713). The addition of the PCasig to the clinical nomogram significantly improved prognostic value (HR, 7.25; 95% CI, 4.54‑11.56; C‑index, 0.782) with an net reclassification improvement of 75.3% (95% CI, 46.8‑104.6%). Furthermore, the endogenous expression of each gene in the PCasig was measured in five PCa cell lines and in normal prostate cells, and these genes exhibited different expression levels relative to one another. In conclusion, an PCasig was identified by mining TCGA and successfully validated in an Oncomine cohort. This PCasig was an independent prognostic factor with a greater prognostic value for all patients regardless of GS than traditional clinical variables, which can improve the performance of clinical nomograms in predicting BCR of patients with GS ≥7.